Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
-
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
-
Aclaris Therapeutics Provides Update on Key Biologic and Oral Inhibitor Clinical Programs
-
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
-
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
-
Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138
-
Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Meeting
-
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
-
Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference
-
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update